Innovative Therapeutics in Oncology and Neuroscience
Bemarituzumab
First-in-Class Antibody Targeting FGFR2b+ in Advanced Gastric/GEJ Cancer
Phase 2 FIGHT of Bemarituzumab + Chemotherapy as 1L Treatment for FGFR2b+ Gastric Cancer
(ITT Patients*, n=155)
Progression Free Survival
Overall Survival
Probability of Progression-Free Survival
1.00
0.75
0.50
0.25
Late-stage
Bema
n=77
MOS,
0.75-
166.2%
19.2
months (13.6-NR) | (9.3-15.9)
(95% CI)
Placebo
n=78
13.5
9-mon rate
Bema
n=77
Placebo
1.00-
n=78
mPFS,
9.5
7.4
months
(95% CI)
(7.3-12.9) (5.4-8.5)
P=0.0727
52.5%
Hazard ratio for disease
progression or death,
0.68 (95% CI, 0.44-1.04)
Probability of Survival
0.50-
33.8
0.00
0
3
6
9
12
15
18
Months
Number at risk
BEMA
77
62
40
28
PLACEBO
78
59
37.
19
12
9
5
13
1
0
0.25-
156.4%
Hazard ratio for death,
0.6 (95% CI, 0.38-0.94)
0.00
0
3
6
69
12
15
5
18
21
24
27
Months
BEMA 77
Number at risk
68
63
51
PLACEBO 78 68 58 44 36 25 13
49
45
39
28
14
4
0
5
2
0
In the ITT patients of FGFR2b+, bemarituzumab + mFOLFOX6 vs mFOLFOX6 numerically improved mPFS to 9.5m vs. 7.4m
(HR 0.68, 95%CI, 0.44-1.04) and improved mOS to 19.2m vs. 13.5m (HR=0.60, 95%CI, 0.38-0.94)
Bemarituzumab demonstrated a tolerable safety profile with manageable ocular adverse events
Intent to Treat (ITT), Median follow-up time of 12.5 months.
35
Source: Wainberg ZA, et al. Lancet Oncol. 2022;23(11):1430-1440.
Clinical Data -
OncologyView entire presentation